Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Allergic Drug Reactions01:27

Allergic Drug Reactions

983
Allergic reactions related to drugs are hypersensitivity responses driven by the immune system and bear no connection to the drug's therapeutic action. While drugs in isolation do not trigger an immune response, they can interact with endogenous proteins to form antigens. These antigens stimulate lymphocytes to produce antibodies. IgE-type antibodies attach themselves to mast cells. Upon subsequent exposure to the same stimulus, the antigen-antibody interaction is initiated, unleashing...
983
Allergic Reactions02:06

Allergic Reactions

28.8K
Overview
28.8K
Hypersensitivities01:30

Hypersensitivities

1.1K
Hypersensitivity, also known as a hypersensitivity reaction or allergic reaction, is a condition where the body's immune system reacts abnormally to a foreign substance. Such substances, that cause hypersensitivity are referred to as an allergen, could be something typically harmless to most people, like pollen or certain foods.
Types of Hypersensitivities
Hypersensitivity reactions are categorized into four types: Type 1, Type 2, Type 3, and Type 4. Each type has a distinct mechanism...
1.1K
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

652
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
652
Desensitization and Tachyphylaxis01:20

Desensitization and Tachyphylaxis

2.2K
Tachyphylaxis is described as a rapid decrease in response to a drug after repeated or continuous administration of the same drug dose. It is a phenomenon where the body becomes less responsive to a particular substance or intervention over time, requiring higher doses or stronger interventions to achieve the same effect. It results from adaptive changes in the body's receptors, signaling pathways, or physiological processes that occur in response to prolonged exposure to a stimulus.
2.2K
Pharmacovigilance01:19

Pharmacovigilance

999
Post-marketing surveillance is a critical component of pharmaceutical regulation, often uncovering unanticipated adverse drug reactions (ADRs) once a drug is widely used over an extended period.
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
999

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Annular elastolytic giant cell granuloma: a rare mimicker of common annular dermatoses.

BMJ case reports·2025
Same author

Symmetrical Drug-Related Intertriginous and Flexural Exanthema (SDRIFE) Unfolded: Diagnostic Pitfalls and Psoriatic Confounders Among Flexural Dermatoses.

Cureus·2025
Same author

Diagnostic and prognostic utility of inflammatory biomarkers in dermatology: A narrative review.

Indian journal of dermatology, venereology and leprology·2025
Same author

Botulinum toxin-induced sarcoidal eruptions: an unusual sequela.

BMJ case reports·2025
Same author

Compound heterozygosity in type-II oculocutaneous albinism.

Indian journal of dermatology, venereology and leprology·2025
Same author

Inked with Melancholy Blues: A Case of Dermatitis Simulata Set in the Realm of Factitious Disorders.

Indian dermatology online journal·2025
Same journal

A Metallic Screw Gun-Traumatic Vertebral Artery Dissection Injury: A Case Report and Literature Review.

Cureus·2026
Same journal

Heparin-Induced Anaphylaxis With Cardiac Arrest in a Patient With Alpha-Gal Syndrome: A Case Report.

Cureus·2026
Same journal

Sodium-Glucose Linked Transporter-2 (SGLT-2) Inhibitor-Associated Unmasking of Myasthenia Gravis in a Patient With Undiagnosed Thymic Follicular Hyperplasia: The First Reported Case.

Cureus·2026
Same journal

Double Trouble: An Uncommon Case of Ocular Toxoplasmosis in a Systemic Lupus Erythematosus (SLE) Patient.

Cureus·2026
Same journal

Immediate Spirometric Response to Submaximal Exercise in Healthy Young Adult Males.

Cureus·2026
Same journal

Determinants of Cardiovascular Events After Simultaneous Pancreas Kidney Transplantation: A Retrospective Cohort Study.

Cureus·2026
See all related articles

Related Experiment Video

Updated: Sep 16, 2025

Microfluidics in Assessing Platelet Function
06:47

Microfluidics in Assessing Platelet Function

Published on: November 8, 2024

1.1K

Ticagrelor-Induced Dermatological Hypersensitivity Reaction.

Snehal Lunge1, Shimoni R Doshi2, Vidyadhar R Sardesai2

  • 1Dermatology, Bharati Vidyapeeth Medical College, Pune, Pune, IND.

Cureus
|July 8, 2025
PubMed
Summary
This summary is machine-generated.

Ticagrelor, an antiplatelet drug, can rarely cause skin rashes. This case report details a patient who developed a rash after starting ticagrelor, which resolved after stopping the medication.

Keywords:
: acute coronary syndromeantiplatelet agentsclopidogreldrug-induced rashticagrelor hypersensitivity

More Related Videos

Updated Technique for Reliable, Easy, and Tolerated Transcranial Electrical Stimulation Including Transcranial Direct Current Stimulation
10:11

Updated Technique for Reliable, Easy, and Tolerated Transcranial Electrical Stimulation Including Transcranial Direct Current Stimulation

Published on: January 3, 2020

11.3K
Recognition of Epidermal Transglutaminase by IgA and Tissue Transglutaminase 2 Antibodies in a Rare Case of Rhesus Dermatitis
10:27

Recognition of Epidermal Transglutaminase by IgA and Tissue Transglutaminase 2 Antibodies in a Rare Case of Rhesus Dermatitis

Published on: December 15, 2011

24.6K

Related Experiment Videos

Last Updated: Sep 16, 2025

Microfluidics in Assessing Platelet Function
06:47

Microfluidics in Assessing Platelet Function

Published on: November 8, 2024

1.1K
Updated Technique for Reliable, Easy, and Tolerated Transcranial Electrical Stimulation Including Transcranial Direct Current Stimulation
10:11

Updated Technique for Reliable, Easy, and Tolerated Transcranial Electrical Stimulation Including Transcranial Direct Current Stimulation

Published on: January 3, 2020

11.3K
Recognition of Epidermal Transglutaminase by IgA and Tissue Transglutaminase 2 Antibodies in a Rare Case of Rhesus Dermatitis
10:27

Recognition of Epidermal Transglutaminase by IgA and Tissue Transglutaminase 2 Antibodies in a Rare Case of Rhesus Dermatitis

Published on: December 15, 2011

24.6K

Area of Science:

  • Cardiology
  • Dermatology
  • Pharmacology

Background:

  • Ticagrelor is a P2Y12 inhibitor commonly prescribed for acute coronary syndromes (ACS).
  • While generally safe and effective compared to clopidogrel, rare adverse events require attention.
  • Skin-related side effects of ticagrelor are infrequently documented.

Observation:

  • A 64-year-old male with coronary artery disease developed a diffuse erythematous rash.
  • The rash appeared two days after initiating ticagrelor post-percutaneous coronary intervention.
  • The patient had no prior history of similar reactions.

Findings:

  • The observed rash was consistent with a drug-induced hypersensitivity reaction.
  • Discontinuation of ticagrelor led to the resolution of the skin eruption.
  • Switching to clopidogrel, along with corticosteroids and antihistamines, facilitated recovery.

Implications:

  • This case underscores the importance of considering ticagrelor as a potential cause of dermatological adverse events.
  • Clinicians should be vigilant for skin reactions in patients treated with ticagrelor.
  • Prompt recognition and management of these reactions are crucial for patient safety.